These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 25506833)
1. Monitoring brain tumor vascular heamodynamic following anti-angiogenic therapy with advanced magnetic resonance imaging in mice. Laufer S; Mazuz A; Nachmansson N; Fellig Y; Corn BW; Bokstein F; Bashat DB; Abramovitch R PLoS One; 2014; 9(12):e115093. PubMed ID: 25506833 [TBL] [Abstract][Full Text] [Related]
2. Magnetic Resonance Elastography reveals effects of anti-angiogenic glioblastoma treatment on tumor stiffness and captures progression in an orthotopic mouse model. Schregel K; Nowicki MO; Palotai M; Nazari N; Zane R; Sinkus R; Lawler SE; Patz S Cancer Imaging; 2020 May; 20(1):35. PubMed ID: 32398076 [TBL] [Abstract][Full Text] [Related]
3. Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. Gossmann A; Helbich TH; Kuriyama N; Ostrowitzki S; Roberts TP; Shames DM; van Bruggen N; Wendland MF; Israel MA; Brasch RC J Magn Reson Imaging; 2002 Mar; 15(3):233-40. PubMed ID: 11891967 [TBL] [Abstract][Full Text] [Related]
4. The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model. Veeravagu A; Hou LC; Hsu AR; Cai W; Greve JM; Chen X; Tse V Neurol Res; 2008 Nov; 30(9):952-9. PubMed ID: 18662497 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of evasion to antiangiogenic therapy in glioblastoma. Rose SD; Aghi MK Clin Neurosurg; 2010; 57():123-8. PubMed ID: 21280504 [No Abstract] [Full Text] [Related]
6. Multivoxel ¹H MR spectroscopy is superior to contrast-enhanced MRI for response assessment after anti-angiogenic treatment of orthotopic human glioma xenografts and provides handles for metabolic targeting. Hamans B; Navis AC; Wright A; Wesseling P; Heerschap A; Leenders W Neuro Oncol; 2013 Dec; 15(12):1615-24. PubMed ID: 24158109 [TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic therapy for glioblastoma. Gerstner ER; Batchelor TT Cancer J; 2012; 18(1):45-50. PubMed ID: 22290257 [TBL] [Abstract][Full Text] [Related]
8. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma. Winkler F; Osswald M; Wick W Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225 [TBL] [Abstract][Full Text] [Related]
9. Vascular Magnetic Resonance Imaging in Brain Tumors During Antiangiogenic Therapy--Are We There Yet? Gerstner ER; Emblem KE; Sorensen GA Cancer J; 2015; 21(4):337-42. PubMed ID: 26222087 [TBL] [Abstract][Full Text] [Related]
10. Characterization of bevacizumab dose response relationship in U87 brain tumors using magnetic resonance imaging measures of enhancing tumor volume and relative cerebral blood volume. Pechman KR; Donohoe DL; Bedekar DP; Kurpad SN; Hoffmann RG; Schmainda KM J Neurooncol; 2011 Nov; 105(2):233-9. PubMed ID: 21533524 [TBL] [Abstract][Full Text] [Related]
11. Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development. Hong YK; Chung DS; Joe YA; Yang YJ; Kim KM; Park YS; Yung WK; Kang JK Clin Cancer Res; 2000 Aug; 6(8):3354-60. PubMed ID: 10955823 [TBL] [Abstract][Full Text] [Related]
12. Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma. Verhoeff JJ; Stalpers LJ; Claes A; Hovinga KE; Musters GD; Peter Vandertop W; Richel DJ; Leenders WP; van Furth WR Eur J Cancer; 2009 Nov; 45(17):3074-80. PubMed ID: 19734041 [TBL] [Abstract][Full Text] [Related]
13. Enigma of a rapid introduction of antiangiogenic therapy with bevacizumab in glioblastoma: a new era in the treatment of malignant brain tumours? Henriksson R; Bergström P; Johansson M; Sandström M Acta Oncol; 2009; 48(1):6-8. PubMed ID: 18932097 [No Abstract] [Full Text] [Related]
14. [Angiogenesis and anti-angiogenic strategies for glioblastoma]. de Boüard S; Guillamo JS Bull Cancer; 2005 Apr; 92(4):360-72. PubMed ID: 15888393 [TBL] [Abstract][Full Text] [Related]
15. Comparison of BOLD cerebrovascular reactivity mapping and DSC MR perfusion imaging for prediction of neurovascular uncoupling potential in brain tumors. Pillai JJ; Zacà D Technol Cancer Res Treat; 2012 Aug; 11(4):361-74. PubMed ID: 22376130 [TBL] [Abstract][Full Text] [Related]
16. Invasion as limitation to anti-angiogenic glioma therapy. Lamszus K; Kunkel P; Westphal M Acta Neurochir Suppl; 2003; 88():169-77. PubMed ID: 14531575 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRI. Boult JKR; Box G; Vinci M; Perryman L; Eccles SA; Jones C; Robinson SP Neoplasia; 2017 Sep; 19(9):684-694. PubMed ID: 28780387 [TBL] [Abstract][Full Text] [Related]
19. Chimeric Mouse model to track the migration of bone marrow derived cells in glioblastoma following anti-angiogenic treatments. Achyut BR; Shankar A; Iskander AS; Ara R; Knight RA; Scicli AG; Arbab AS Cancer Biol Ther; 2016; 17(3):280-90. PubMed ID: 26797476 [TBL] [Abstract][Full Text] [Related]
20. Angiogenesis inhibitor DC101 delays growth of intracerebral glioblastoma but induces morbidity when combined with irradiation. Verhoeff JJ; Stalpers LJ; Van Noorden CJ; Troost D; Ramkema MD; van Bree C; Song JY; Donker M; Chekenya M; Vandertop WP; Richel DJ; van Furth WR Cancer Lett; 2009 Nov; 285(1):39-45. PubMed ID: 19473756 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]